Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigate Risperidone for the Treatment of Schizophrenia in Adolescents

This study has been completed.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: July 19, 2004
Last updated: June 6, 2011
Last verified: January 2011